Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GRT-C903 |
Trade Name | |
Synonyms | GRTC903|GRT C903 |
Drug Descriptions |
GRT-C903 is a neoantigen cancer vaccine, which activates cytotoxic T-lymphocyte to kill cancer cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C165514 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Aldesleukin Anti-KRAS G12D TCR cells GRT-C903 GRT-R904 | 0 | 1 |
Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 | Aldesleukin Anti-KRAS G12V TCR cells GRT-C903 GRT-R904 | 0 | 1 |
GRT-C903 | GRT-C903 | 0 | 0 |
GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | GRT-C903 GRT-R904 Ipilimumab Nivolumab | 0 | 1 |